IRAK4 kinase inhibitor and preparation method therefor
AssigneeGuangzhou Yufan Nantu Biotechnologies Co., Ltd
InventorsXingyu Lin, Tingting Lu
Life of this patent
Estimating the term…
Abstract
The present invention provides a compound of general formula I, and a pharmaceutically acceptable salt, a stereoisomer, an ester, a prodrug, a solvate and a deuterated compound thereof, wherein the compound is an IRAK4 kinase inhibitor, and can be used for preventing and/or treating diseases related to IRAK4, such as autoimmune diseases, inflammatory diseases, cancers, heteroimmune diseases, thromboembolism, atherosclerosis, myocardial infarction and metabolic syndrome.
Claims10
A compound, or a pharmaceutically acceptable salt thereof, wherein the compound has the following structural formula:
- wherein,
- R2 is selected from
- R5 is selected from —H, —CH3,
- R6 is selected from —CF3, —CHF2, —CH2F, —CH2CF3, —CN,
- and
- R7 is —H.
A compound, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the following structures:
A compound, or a pharmaceutically acceptable salt, a stereoisomer, a solvate, or a deuterated compound thereof, wherein the compound has the following structural formula:
- wherein:
- R2 is C3-8 cycloalkyl or heterocycloalkyl, wherein H of the groups can be substituted with one or two or more of the following substituents:
- —OH, —NH2, halogen, —CN, —NO2, —CF3, —OCF3, ═O, —N alkyl, —O alkyl, —S alkyl, —SO-alkyl, —SO2-alkyl, —COO-alkyl, —CON alkyl, —CO-alkyl, —OCO-alkyl, —N-alkyl-CON-alkyl, —N-alkyl-CO-alkyl, —N alkyl-SO2-alkyl, substituted or unsubstituted aryl, and substituted or unsubstituted cycloalkyl;
- R6 is selected from C3-8 cycloalkyl or heterocycloalkyl, wherein H of the groups can be substituted with one or two or more of the following substituents:
- —OH, —NH2, halogen, —CN, —NO2, —CF3, —OCF3, ═O, —N alkyl, —O alkyl, —S alkyl, —SO-alkyl, —SO2-alkyl, —COO-alkyl, —CON alkyl, —CO-alkyl, —OCO-alkyl, —N-alkyl-CON-alkyl, —N alkyl-CO-alkyl, —N alkyl-SO2-alkyl, substituted or unsubstituted aryl, and substituted or unsubstituted cycloalkyl,
- R1, R3, and R4 are each —H,
- R7 is —H, and
- R5 is —H or —CH3.
Dependencies are inferred from the claim text.